Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.04 +0.70 (+3.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

22 23 Next >

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies ↗

March 18, 2025

The patient also had a recent CMV infection, which the company said could have contributed.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 18, 2025

Via Benzinga

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases ↗

March 10, 2025

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.

Via Benzinga

SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations ↗

March 04, 2025

A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

March 04, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

Via StockStory

Topics Artificial Intelligence

8 Analysts Have This To Say About Sarepta Therapeutics ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

2 Growth Stocks to Buy Hand Over Fist in February ↗

February 09, 2025

Via The Motley Fool

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript ↗

February 26, 2025

SRPT earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue

February 26, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was...

Via StockStory

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

February 25, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

February 19, 2025

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

Via MarketBeat

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

January 15, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts ↗

December 19, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years ↗

January 27, 2025

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Via Benzinga

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗

January 08, 2025

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Via Benzinga

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst ↗

December 13, 2024

Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.

Via Benzinga

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Via Benzinga

Analyst Expectations For Sarepta Therapeutics's Future ↗

November 25, 2024

Via Benzinga

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.

Via Benzinga

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30 ↗

November 30, 2024

Via Talk Markets

Topics Stocks / Equities

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗

November 26, 2024

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....

Via Benzinga

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

November 26, 2024

Via Benzinga

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗

November 26, 2024

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Via Investor's Business Daily

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

November 25, 2024

Via Benzinga

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 07, 2024

Via Benzinga

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 07, 2024

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

SRPT earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today